Author’s response to reviews

Title: MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

Authors:

Zsófia Pénzváltó (penzvaltozsofi@gmail.com)
András Lánczky (lanbenator@gmail.com)
Julianna Lénárt (lenartiuli@gmail.com)
Nóra Meggyesházi (meggyeshazinora@gmail.com)
Tibor Krenács (krenacst@gmail.com)
Norbert Szoboszlai (szobosz@chem.elte.hu)
Carsten Denkert (carsten.denkert@charite.de)
Imre Pete (pete@oncol.hu)
Balázs Gyorffy (zsalab2@yahoo.com)

Version: 3
Date: 22 September 2014

Author’s response to reviews: see over
Dear Editors,

Thank you for the opportunity to revise our manuscript in response to the Handling Editor’s comments.

Please find below a point-by-point answer to the concerns:

-"Please can you clarify the full name of the institutional ethics committee which approved your tissue sample collection."

The National Institute of Oncology, Regional and Institutional Committee of Science and Research Ethics approved the sample collection. We corrected it in the methods section.

-"Please clarify the source of your cell lines in your methods section."

The cell lines were obtained from ATCC, we supplemented the methods section with this information.

-"Please anonymize suppl table 2 by removing age."

We removed the "age" column from the table, and the supplemental table legend has been corrected at the end of the manuscript.

In addition to the comments from the editor, we discovered some minor mistakes in the authors’ affiliations and in the supplemental table 1 (where letter µ was used instead of μ). We corrected these too.

We hope that we have sufficiently addressed the concerns and that our manuscript will now be eligible for publication.

Sincerely yours,
Balázs Győrffy